CA2301852A1 - Angiogenesis promoters and angiogenesis potentiators - Google Patents

Angiogenesis promoters and angiogenesis potentiators Download PDF

Info

Publication number
CA2301852A1
CA2301852A1 CA002301852A CA2301852A CA2301852A1 CA 2301852 A1 CA2301852 A1 CA 2301852A1 CA 002301852 A CA002301852 A CA 002301852A CA 2301852 A CA2301852 A CA 2301852A CA 2301852 A1 CA2301852 A1 CA 2301852A1
Authority
CA
Canada
Prior art keywords
angiogenesis
potentiators
promoters
acceptable salt
pharmacologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002301852A
Other languages
French (fr)
Other versions
CA2301852C (en
Inventor
Yasuhiro Egi
Hideaki Kido
Kazutaka Hayashi
Yoshiji Kubo
Norifumi Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Yoshitomi Pharmaceutical Industries Ltd.
Nissan Chemical Industries, Ltd.
Yasuhiro Egi
Hideaki Kido
Kazutaka Hayashi
Yoshiji Kubo
Norifumi Nakamura
Welfide Corporation
Mitsubishi Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoshitomi Pharmaceutical Industries Ltd., Nissan Chemical Industries, Ltd., Yasuhiro Egi, Hideaki Kido, Kazutaka Hayashi, Yoshiji Kubo, Norifumi Nakamura, Welfide Corporation, Mitsubishi Pharma Corporation filed Critical Yoshitomi Pharmaceutical Industries Ltd.
Publication of CA2301852A1 publication Critical patent/CA2301852A1/en
Application granted granted Critical
Publication of CA2301852C publication Critical patent/CA2301852C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

An angiogenesis promoter and angiogenesis potentiator containing a pyridazinone compound of the formula (I) (see formula I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof, as an active ingredient.
The pyridazinone compound (I) and a pharmacologically acceptable salt thereof in the present invention promote angiogenesis and potentiate the angiogenic effect of a drug having such effect, and are useful as an angiogenesis promoter and angiogenesis potentiator.
CA002301852A 1997-08-28 1998-08-26 Angiogenesis promoters and angiogenesis potentiators Expired - Fee Related CA2301852C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP23264497 1997-08-28
JP9/232644 1997-08-28
PCT/JP1998/003820 WO1999011268A1 (en) 1997-08-28 1998-08-26 Neovascularization promoters and neovascularization potentiators

Publications (2)

Publication Number Publication Date
CA2301852A1 true CA2301852A1 (en) 1999-03-11
CA2301852C CA2301852C (en) 2007-07-10

Family

ID=16942531

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002301852A Expired - Fee Related CA2301852C (en) 1997-08-28 1998-08-26 Angiogenesis promoters and angiogenesis potentiators

Country Status (13)

Country Link
US (1) US6284758B1 (en)
EP (1) EP1025847B1 (en)
JP (1) JP4352613B2 (en)
KR (1) KR100559192B1 (en)
CN (1) CN1142779C (en)
AT (1) ATE307584T1 (en)
AU (1) AU8886298A (en)
CA (1) CA2301852C (en)
DE (1) DE69832089T2 (en)
DK (1) DK1025847T3 (en)
ES (1) ES2247716T3 (en)
TW (1) TW490303B (en)
WO (1) WO1999011268A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100633869B1 (en) * 1998-12-07 2006-10-16 닛산 가가쿠 고교 가부시키 가이샤 Remedial agent for erectile dysfunction
EP1698339A4 (en) * 2003-12-26 2009-06-17 Nissan Chemical Ind Ltd Neutrophilia inhibitor
WO2005074938A1 (en) * 2004-02-09 2005-08-18 Nissan Chemical Industries, Ltd. Drug for inhibiting vascular intimal hyperplasia
AU2006270221B2 (en) 2005-07-15 2012-01-19 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
EP2019657B1 (en) 2006-04-26 2015-05-27 Micell Technologies, Inc. Coatings containing multiple drugs
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
EP2111184B1 (en) 2007-01-08 2018-07-25 Micell Technologies, Inc. Stents having biodegradable layers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CN101622003B (en) * 2007-02-28 2012-03-21 日本株式会社Ltt生物医药 Therapeutic agent for ameliorating prognosis after lower limb amputation surgery
CA2688314C (en) 2007-05-25 2013-12-03 Micell Technologies, Inc. Polymer films for medical device coating
US8685432B2 (en) * 2008-03-25 2014-04-01 University Of Utah Research Foundation Controlled release tissue graft combination biomaterials
MX350637B (en) 2008-04-17 2017-09-11 Micell Technologies Inc Stents having bioabsorbable layers.
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
WO2010111232A2 (en) 2009-03-23 2010-09-30 Micell Technologies, Inc. Drug delivery medical device
CN102481195B (en) 2009-04-01 2015-03-25 米歇尔技术公司 Drug delivery medical device
CA2759015C (en) 2009-04-17 2017-06-20 James B. Mcclain Stents having controlled elution
WO2011097103A1 (en) 2010-02-02 2011-08-11 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US9554888B2 (en) 2010-04-20 2017-01-31 University Of Utah Research Foundation Phase separation sprayed scaffold
WO2011133655A1 (en) 2010-04-22 2011-10-27 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US20130172853A1 (en) 2010-07-16 2013-07-04 Micell Technologies, Inc. Drug delivery medical device
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US9889235B2 (en) 2013-02-05 2018-02-13 University Of Utah Research Foundation Implantable devices for bone or joint defects
CN110269959A (en) 2013-03-12 2019-09-24 脉胜医疗技术公司 Bioabsorbable biomedical implants
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07107055B1 (en) 1990-04-25 1995-11-15
CA2063055A1 (en) * 1991-05-22 1992-11-23 Jacob Eyal Peptides having thrombospondin-like activity and their therapeutic use
JP3666042B2 (en) * 1994-01-25 2005-06-29 日産化学工業株式会社 Pyridazinone derivatives
IL112695A (en) * 1994-02-22 1999-04-11 Green Cross Corp Pharmaceutical compositions containing pyridazinone derivatives

Also Published As

Publication number Publication date
EP1025847B1 (en) 2005-10-26
CN1142779C (en) 2004-03-24
US6284758B1 (en) 2001-09-04
TW490303B (en) 2002-06-11
ES2247716T3 (en) 2006-03-01
DK1025847T3 (en) 2006-02-13
CN1277553A (en) 2000-12-20
AU8886298A (en) 1999-03-22
ATE307584T1 (en) 2005-11-15
WO1999011268A1 (en) 1999-03-11
JP4352613B2 (en) 2009-10-28
KR20010023331A (en) 2001-03-26
DE69832089T2 (en) 2006-07-20
DE69832089D1 (en) 2005-12-01
EP1025847A1 (en) 2000-08-09
KR100559192B1 (en) 2006-03-13
EP1025847A4 (en) 2003-01-08
CA2301852C (en) 2007-07-10

Similar Documents

Publication Publication Date Title
CA2301852A1 (en) Angiogenesis promoters and angiogenesis potentiators
CA2288122A1 (en) Neuropeptide y receptor antagonist
CA2250586A1 (en) Meta-substituted phenylene sulphonamide derivatives
EP0930309A4 (en) Taxane derivatives and drugs containing the same
IL143958A0 (en) Heteroaromatic derivatives having an inhibitory activity against hiv integrase
MXPA04004674A (en) Cannabinoid receptor ligands.
HU9701081D0 (en) Pharmaceutical composition of antitumoral activity
AU2300699A (en) Amidino derivatives and drugs containing the same as the active ingredient
CA2348735A1 (en) Heterocyclic potassium channel inhibitors
CA2349330A1 (en) Nitrogen containing heterobicycles as factor xa inhibitors
AU2002235140A1 (en) Fluidic self-assembly of active antenna
CA2263404A1 (en) Pharmaceutical composition comprising coenzyme q10
CA2238553A1 (en) Cholesterol-lowering composition
IL132682A0 (en) Topical compositions
EP1230925B8 (en) Use of a trifluridine derivative alone or combined with a thymidine phosphorylase inhibitor for the treatment of hiv
EP0992240A4 (en) Therapeutic agent for erection failure
CA2237189A1 (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists
AU6309698A (en) Drugs containing aminopyridine derivatives as the active ingredient
AU3078000A (en) Heterocyclic compounds and antitumor agents containing the same as the active ingredient
WO2003024933A1 (en) 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
AU4806497A (en) Glyoxylic compound comprising one or more active ingredient
EP1008345A4 (en) Antiallergic agents
EP0702014A4 (en) Dc-89 derivative
EP0816366A4 (en) Imidazothiazole compounds
EP1262482A4 (en) Novel compound having antimalarial activity

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160826